Search Results - "Lauand, Felipe" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM

The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM

by Renard, Eric, Ikegami, Hiroshi, Daher Vianna, André Gustavo, Pozzilli, Paolo, Brette, Sandrine, Bosnyak, Zsolt, Lauand, Felipe, Peters, Anne, Pilorget, Valerie, Jurišić‐Eržen, Dubravka, Kesavadev, Jothydev, Seufert, Jochen, Wilmot, Emma G.
Published in Diabetes/metabolism research and reviews (01.10.2021)

Get full text

Journal Article

1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes

1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes

by HARRIS, STEWART B., BERARD, LORI, WESTERBACKA, JUKKA, BOSNYAK, ZSOLT, MELAS-MELT, LYDIE, LAUAND, FELIPE, BAILEY, TIMOTHY S., KHUNTI, KAMLESH
Published in Diabetes (New York, N.Y.) (01.06.2019)

Get full text

Journal Article

Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials

Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials

by Yang, Wenying, Guo, Xiaohui, Lauand, Felipe, Li, Lingyu, Fang, Hexin, Du, Qin, Kang, Lei
Published in Diabetes, obesity & metabolism (01.04.2024)

Get full text

Journal Article

Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials

Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials

by Giorgino, Francesco, Guja, Cristian, Aydın, Hasan, Lauand, Felipe, Melas-Melt, Lydie, Rosenstock, Julio
Published in Diabetes research and clinical practice (01.03.2024)

Get full text

Journal Article

1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)-The SoliD Randomized Controlled Trial

1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)-The SoliD Randomized Controlled Trial

by Liu, Ming, Gu, Weijun, Chen, Li, Li, Yanbing, Kuang, Hongyu, Du, Jianling, Alvarez, Agustina, Lauand, Felipe, Souhami, Elisabeth, Zhang, Jiewen, Xu, Weiya, Du, Qin, Mu, Yiming
Published in Diabetes (New York, N.Y.) (01.06.2024)

Get full text

Journal Article

1880-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin-A Systemic Literature Review and Network Meta-analysis

1880-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin-A Systemic Literature Review and Network Meta-analysis

by Home, Philip, Lauand, Felipe, Djaballah, Khier, Bourhis, Francois, Li, Xuan, Hafidh, Khadija, Mehta, Roopa, Faraoun, Khadra, Anaforoglu, Inan, Pourrahmat, Mir-Masoud
Published in Diabetes (New York, N.Y.) (01.06.2024)

Get full text

Journal Article

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes-Soli De-escalation

by Giorgino, Francesco, Lauand, Felipe, Servera, Soraly, Li, Xuan, Taybani, Zoltán, Cheng, Alice YY, Fonseca, Vivian, Tebaibia, Amar, Anaforoglu, Inan
Published in Diabetes (New York, N.Y.) (01.06.2024)

Get full text

Journal Article

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

by Danne, Thomas, Matsuhisa, Munehide, Sussebach, Christian, Goyeau, Harmonie, Lauand, Felipe, Niemoeller, Elisabeth, Bolli, Geremia B.
Published in Diabetes, obesity & metabolism (01.10.2020)

Get full text

Journal Article

The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial

The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial

by Liu, Ming, Gu, Weijun, Chen, Li, Li, Yanbing, Kuang, Hongyu, Du, Jianling, Alvarez, Agustina, Lauand, Felipe, Souhami, Elisabeth, Zhang, Jiewen, Xu, Weiya, Du, Qin, Mu, Yiming
Published in Diabetes, obesity & metabolism (01.09.2024)

Get full text

Journal Article

Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials

Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials

by Haluzík, Martin, Al‐Sofiani, Mohammed E., Cheng, Alice Y. Y., Lauand, Felipe, Melas‐Melt, Lydie, Rosenstock, Julio
Published in Diabetes, obesity & metabolism (08.09.2024)

Get full text

Journal Article

775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis

775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis

by MUNSHI, MEDHA, RITZEL, ROBERT, MCCRIMMON, RORY J., HRAMIAK, IRENE, LAUAND, FELIPE, MELAS-MELT, LYDIE, SOUHAMI, ELISABETH, ROSENSTOCK, JULIO
Published in Diabetes (New York, N.Y.) (20.06.2023)

Get full text

Journal Article

799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis

799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis

by HRAMIAK, IRENE, FRIAS, JUAN P., AYDIN, HASAN, LAUAND, FELIPE, MELAS-MELT, LYDIE, SOUHAMI, ELISABETH, HALUZIK, MARTIN, ROSENSTOCK, JULIO
Published in Diabetes (New York, N.Y.) (20.06.2023)

Get full text

Journal Article

773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis

773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis

by GIORGINO, FRANCESCO, GUJA, CRISTIAN, DAVIES, MELANIE J., AYDIN, HASAN, LAUAND, FELIPE, SOUHAMI, ELISABETH, MELAS-MELT, LYDIE, ARODA, VANITA R., ROSENSTOCK, JULIO
Published in Diabetes (New York, N.Y.) (20.06.2023)

Get full text

Journal Article

788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi

788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi

by CHENG, ALICE Y., FRIAS, JUAN P., GUJA, CRISTIAN, LAUAND, FELIPE, MELAS-MELT, LYDIE, ALVAREZ, AGUSTINA, SOUHAMI, ELISABETH, ROSENSTOCK, JULIO
Published in Diabetes (New York, N.Y.) (20.06.2023)

Get full text

Journal Article

800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial

800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial

by HALUZIK, MARTIN, FRIAS, JUAN P., CHENG, ALICE Y., AL-SOFIANI, MOHAMMED, LAUAND, FELIPE, MELAS-MELT, LYDIE, SOUHAMI, ELISABETH, ROSENSTOCK, JULIO
Published in Diabetes (New York, N.Y.) (20.06.2023)

Get full text

Journal Article

Impact of X-Ray Exposure From Computed Tomography on Wearable Insulin Delivery Devices

Impact of X-Ray Exposure From Computed Tomography on Wearable Insulin Delivery Devices

by Dong, Frank, Johnson, Paul, Fong, Grant, Nguyen, Alex, Lauand, Felipe, Vienneau, Todd
Published in Journal of diabetes science and technology (26.04.2023)

Get full text

Journal Article

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis

by Guo, Xiaohui, Yang, Wenying, Zhang, Junqing, Dong, Xiaolin, Liu, Ming, Gu, Shenghong, Lauand, Felipe, Li, Lingyu, Huang, Qiong, Kang, Lei, Souhami, Elisabeth
Published in Diabetes, obesity & metabolism (01.07.2023)

Get full text

Journal Article

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis

by Guo, Xiaohui, Yang, Wenying, Zhang, Junqing, Dong, Xiaolin, Liu, Ming, Gu, Shenghong, Lauand, Felipe, Li, Lingyu, Huang, Qiong, Kang, Lei, Souhami, Elisabeth
Published in Diabetes, obesity & metabolism (01.07.2023)

Get full text

Journal Article

Lower risk of severe hypoglycaemia with insulin glargine 300U/mL versus glargine 100U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

Lower risk of severe hypoglycaemia with insulin glargine 300U/mL versus glargine 100U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

by Danne, Thomas, Matsuhisa, Munehide, Sussebach, Christian, Harmonie Goyeau, Lauand, Felipe, Niemoeller, Elisabeth, Bolli, Geremia B
Published in Diabetes, obesity & metabolism (01.10.2020)

Get full text

Journal Article

1514-P: Suboptimal Glycemic Control and High Prevalence of Diabetes Complications in Adults with Type 1 Diabetes (T1D) in the SAGE Study

1514-P: Suboptimal Glycemic Control and High Prevalence of Diabetes Complications in Adults with Type 1 Diabetes (T1D) in the SAGE Study

by RENARD, ERIC, BOSNYAK, ZSOLT, LAUAND, FELIPE, POZZILLI, PAOLO, IKEGAMI, HIROSHI, KESAVADEV, JOTHYDEV, VIANNA, ANDRE G.
Published in Diabetes (New York, N.Y.) (01.06.2020)

Get full text

Journal Article